Biblio
Export 1465 results:
Author Title Type [ Year] Filters: First Letter Of Last Name is H [Clear All Filters]
“A Remotely Coached Multimodal Lifestyle Intervention for Alzheimer's Disease Ameliorates Functional and Cognitive Outcomes.”, J Alzheimers Dis, vol. 96, no. 2, pp. 591-607, 2023.
, “A Remotely Coached Multimodal Lifestyle Intervention for Alzheimer's Disease Ameliorates Functional and Cognitive Outcomes.”, J Alzheimers Dis, vol. 96, no. 2, pp. 591-607, 2023.
, “Retinal Functional and Structural Neural Indices: Potential Biomarkers for the Monitoring of Cerebral Neurodegeneration: The Maastricht Study.”, J Alzheimers Dis, vol. 93, no. 4, pp. 1471-1483, 2023.
, “The Role of Interferon-α in Neurodegenerative Diseases: A Systematic Review.”, J Alzheimers Dis, vol. 94, no. s1, pp. S45-S66, 2023.
, “S1PR2 Regulates Autophagy Through the AKT/mTOR Pathway to Promote Pathological Damage in Alzheimer's Disease.”, J Alzheimers Dis, vol. 96, no. 4, pp. 1489-1504, 2023.
, “S1PR2 Regulates Autophagy Through the AKT/mTOR Pathway to Promote Pathological Damage in Alzheimer's Disease.”, J Alzheimers Dis, vol. 96, no. 4, pp. 1489-1504, 2023.
, “Safety, Feasibility, and Potential Clinical Efficacy of 40 Hz Invisible Spectral Flicker versus Placebo in Patients with Mild-to-Moderate Alzheimer's Disease: A Randomized, Placebo-Controlled, Double-Blinded, Pilot Study.”, J Alzheimers Dis, vol. 92, no. 2, pp. 653-665, 2023.
, “Safety, Feasibility, and Potential Clinical Efficacy of 40 Hz Invisible Spectral Flicker versus Placebo in Patients with Mild-to-Moderate Alzheimer's Disease: A Randomized, Placebo-Controlled, Double-Blinded, Pilot Study.”, J Alzheimers Dis, vol. 92, no. 2, pp. 653-665, 2023.
, “Safety, Feasibility, and Potential Clinical Efficacy of 40 Hz Invisible Spectral Flicker versus Placebo in Patients with Mild-to-Moderate Alzheimer's Disease: A Randomized, Placebo-Controlled, Double-Blinded, Pilot Study.”, J Alzheimers Dis, vol. 92, no. 2, pp. 653-665, 2023.
, “Serotonin Degeneration and Amyloid-β Deposition in Mild Cognitive Impairment: Relationship to Cognitive Deficits.”, J Alzheimers Dis, vol. 96, no. 1, pp. 215-227, 2023.
, “Soluble TREM2, Alzheimer's Disease Pathology, and Risk for Progression of Cerebral Small Vessel Disease: A Longitudinal Study.”, J Alzheimers Dis, vol. 92, no. 1, pp. 311-322, 2023.
, “TDP-43 Pathology in the Setting of Intermediate and High Alzheimer's Disease Neuropathologic Changes: A Preliminary Evaluation Across Ethnoracial Groups.”, J Alzheimers Dis, vol. 91, no. 4, pp. 1291-1301, 2023.
, “TDP-43 Pathology in the Setting of Intermediate and High Alzheimer's Disease Neuropathologic Changes: A Preliminary Evaluation Across Ethnoracial Groups.”, J Alzheimers Dis, vol. 91, no. 4, pp. 1291-1301, 2023.
, “Timing of Alzheimer's Disease by Intellectual Disability Level in Down Syndrome.”, J Alzheimers Dis, vol. 95, no. 1, pp. 213-225, 2023.
, “Timing of Alzheimer's Disease by Intellectual Disability Level in Down Syndrome.”, J Alzheimers Dis, vol. 95, no. 1, pp. 213-225, 2023.
, “Timing of Alzheimer's Disease by Intellectual Disability Level in Down Syndrome.”, J Alzheimers Dis, vol. 95, no. 1, pp. 213-225, 2023.
, “Timing of Alzheimer's Disease by Intellectual Disability Level in Down Syndrome.”, J Alzheimers Dis, vol. 95, no. 1, pp. 213-225, 2023.
, “Vacuolar Protein-Sorting Proteins Are Reduced Even Before Cognitive Decline in a Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 96, no. 3, pp. 1011-1017, 2023.
, “Validation of a Multivariate Prediction Model of the Clinical Progression of Alzheimer's Disease in a Community-Dwelling Multiethnic Cohort.”, J Alzheimers Dis, vol. 95, no. 1, pp. 93-117, 2023.
, “3-Hydroxyacyl-CoA and Alcohol Dehydrogenase Activities of Mitochondrial Type 10 17β-Hydroxysteroid Dehydrogenase in Neurodegeneration Study.”, J Alzheimers Dis, vol. 88, no. 4, pp. 1487-1497, 2022.
, “5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA as Diagnostic Biomarkers for Late-Onset Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 573-585, 2022.
, “Antihypertensive Medication Class and the Risk of Dementia and Cognitive Decline in Older Adults: A Secondary Analysis of the Prospective HELIAD Cohort.”, J Alzheimers Dis, vol. 89, no. 2, pp. 709-719, 2022.
, “Antihypertensive Medication Class and the Risk of Dementia and Cognitive Decline in Older Adults: A Secondary Analysis of the Prospective HELIAD Cohort.”, J Alzheimers Dis, vol. 89, no. 2, pp. 709-719, 2022.
, “APOEɛ4 Allele Moderates the Association Between Basal Forebrain Nuclei Volumes and Allocentric Navigation in Older Adults Without Dementia.”, J Alzheimers Dis, vol. 86, no. 1, pp. 155-171, 2022.
, “Association of Brain Volume and Retinal Thickness in the Early Stages of Alzheimer's Disease.”, J Alzheimers Dis, vol. 91, no. 2, pp. 743-752, 2022.
,